Interleukin-5 in the Pathophysiology of Severe Asthma.

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. · 2019

Read Interleukin-5 in the Pathophysiology of Severe Asthma. by Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6927944.txt.

Description

Pelaia and co-authors review interleukin-5 in severe asthma. Their review appeared in Frontiers in Physiology. Interleukin-5, or IL-5, drives eosinophil biology. It shapes their growth, recruitment, survival, and degranulation. Those cells fuel eosinophilic airway inflammation.

Recent work has clarified how IL-5 acts. It builds, sustains, and amplifies the inflammatory response. That central role makes it a prime drug target. Some therapies block IL-5 itself. Mepolizumab and reslizumab work that way. Benralizumab instead blocks its receptor. These biologics can help patients with severe T2-high asthma. Such asthma often resists inhaled and systemic steroids. The review weighs the gains for that group.

Catalog record

CREATORPelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6927944

Browse the full library · About the Tower of Babel